IGI Logo

Cohance Lifesciences is currently trading at Rs. 446.05, up by 4.60 points or 1.04% from its previous closing of Rs. 441.45 on the BSE.

The scrip opened at Rs. 441.25 and has touched a high and low of Rs. 448.40 and Rs. 428.45 respectively. So far 48171 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 714.60 on 10-Nov-2025 and a 52 week low of Rs. 267.85 on 09-Mar-2026.

Last one week high and low of the scrip stood at Rs. 458.45 and Rs. 415.80 respectively. The current market cap of the company is Rs. 16945.24 crore.

The promoters holding in the company stood at 57.48%, while Institutions and Non-Institutions held 26.57% and 15.95% respectively.

Cohance Lifesciences has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its manufacturing facility at Pashamylaram, Hyderabad. The USFDA has classified the inspection outcome as Voluntary Action Indicated (VAI).

Earlier, the USFDA had conducted an inspection of the aforesaid manufacturing facility from July 27, 2026, to August 5, 2026.

Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization.